TROY, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the third quarter of 2025.Q3 revenue of $935.0 million, down 9.9% year-over-year; excluding discrete U.S. federal government and large customer impacts, underlying revenue down approximately 2.0% year-over-year Underlying revenue reflects continued growth in the Education segment, a consistent rate of decline in the SET segment, and a modest decline in the ETM segment Q3 adjusted SG&A decline of 9.7% reflects increased momentum on structural and demand-driven expense optimization initiatives, including legacy acquisition integration, technology modernization, and process efficiencies Q3 operating loss of $102.1 million including $102.0 million of non-cash goodwill impairment...

FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 diabetes submitted to FDA Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2025, and provided an update on key corporate milestones and accomplishments.  “Lexicon ushered in 2025 with an ambitious slate of objectives embracing and driving our renewed R&D focus,”...

Achieved record levels of consolidated net revenue, gross profit and Adjusted EBITDA Net revenue in Q3 2025 increased by 9% quarter-over-quarter and 6% year-over-year Generated record-high net revenue in Israel, where PEACE NATURALS® remains the number one cannabis brand1 Industry-leading balance sheet with $824 million in total cash and cash equivalents and short-term investments TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2025 third quarter business results. “Our third quarter results reflect continued progress towards our objectives, with the business reaching record levels of net revenue, gross profit and adjusted EBITDA generation, driven by the seventh consecutive quarter of record net revenue at Cronos Israel, as well as by continued...

Organic Sales and Margin Expansion Drive EPS Growth, FY26 Outlook Increased CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) — Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today reported results for the quarter ended September 30, 2025, that included the following highlights (compared with the prior year period): Fiscal 2026 First Quarter Highlights:Sales were a record $5.1 billion; organic sales growth was 5% Net income was $808 million, an increase of 16%, or $927 million adjusted, an increase of 14% EPS were $6.29, an increase of 18%, or a record $7.22 adjusted, an increase of 16% Segment operating margin was 24.2%, an increase of 160 bps, or 27.4% adjusted, an increase of 170 bps Cash flow from operations was $782 million or 15.4% of sales Repurchased $475 million of shares“Our...

Net Revenue of $65.1 million  Gross Profit Margin of 52.1% from continuing operations, up 110 basis points from 51.0% in the third quarter of 2024 Net Cash provided from continuing operations of $7.1 million and Free Cash Flow¹ of $4.9 million 13th consecutive quarter of positive Cash Flow from continuing operations and 9th consecutive quarter of positive Free Cash Flow¹ During the quarter, completed a $79 million non-dilutive refinancing of existing debt with an additional uncommitted term loan facility of up to $35 million for strategic M&A TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today reported its financial results for the third quarter ended September 30, 2025. All amounts are...

Third quarter cloud subscriptions revenue increased 21% year-over-year to $113.6 millionThird quarter total revenue increased 21% year-over-year to $187.0 million MCLEAN, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) — Appian (Nasdaq: APPN) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights:Revenue: Cloud subscriptions revenue was $113.6 million, up 21% compared to the third quarter of 2024. Total subscriptions revenue, which includes sales of our cloud subscriptions, on-premises term license subscriptions, and maintenance and support, increased 20% year-over-year to $147.2 million. Professional services revenue was $39.8 million, up 29% compared to the third quarter of 2024. Total revenue was $187.0 million, up 21% compared to the third quarter of 2024. Cloud subscriptions...

Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of $94.7 million Separately announced upcoming retirement of CEO, departure of President and appointment of prior CEO to Executive Chairperson; Board conducting CEO search Announced PDUFA dates for its new formulation of piflufolastat F 18 PSMA PET imaging agent; for MK-6240, its F 18 tau-targeted positron emission tomography (PET) imaging agent; and for LNTH-2501, its Ga 68 PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs) Closed acquisition of Life Molecular Imaging in July, immediately expanding near- and long-term growth profile and commercial portfolio Repurchased $100 million of shares of common...

CALGARY, Alberta, Nov. 06, 2025 (GLOBE NEWSWIRE) — TransAlta Corporation (TransAlta or the Company) (TSX: TA) (NYSE: TAC) today reported its financial results for the third quarter ended Sept. 30, 2025. “Our business delivered solid operational performance during the third quarter, demonstrating the Company’s resilience in the face of challenging market conditions. Our Alberta portfolio’s hedging strategy and active asset optimization continued to generate realized prices well above spot prices, while availability remained high across the fleet. Although Alberta power prices remain suppressed, our assets continue to perform well, and we remain confident in achieving results within our 2025 Outlook range,” said John Kousinioris, President and Chief Executive Officer. “We are pleased with the continued progress on a number...

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated  Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) ongoing, with initial data from both trials expected in H2 2026 Regulatory clearance obtained to initiate CLYM116 Phase 1 trial; anticipate dosing first subject by year-end, with initial data expected mid-2026 Leadership team strengthened with the appointments of Susan Altschuller, Ph.D., MBA, Chief Financial Officer, Adam Villa SVP, Technical Operations, and Ashley Jones SVP, People & Workforce Strategy Cash runway expected through 2027, anticipated to fund company through multiple upcoming clinical milestones WELLESLEY HILLS, Mass., Nov. 06,...

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarter October 2025 ending cash and cash equivalents of over $100 million; ended Q3 2025 with $85.0 million in cash and cash equivalents after closing of $57.5 million public offering in August 2025, with additional $29.8 million gross proceeds from usage of at-the-market (ATM) offering facility in October 2025 Announced U.S. IND clearance and alignment with U.S. FDA on pivotal clinical program for VYD2311, a vaccine-alternative antibody to prevent COVID REVOLUTION, Invivyd’s development program for VYD2311, comprises the DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials, which are...